Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ™

Key Takeaways

• Lesion Inspection Tool enables lesion‑level plaque composition quantification
• Plaque‑IQ validated against histology, the only FDA‑cleared CTA algorithm
• Quantifies high‑risk features like lipid‑rich necrotic core (LRNC)
• Supports personalized treatment decisions for coronary and carotid disease

Pulse Analysis

Elucid’s new Lesion Inspection Tool brings lesion‑specific plaque analysis from research labs into everyday cardiology practice. By allowing physicians to isolate and quantify the composition of individual plaques in coronary and carotid arteries, the software moves beyond traditional aggregate plaque scores that only hint at overall disease burden. This granularity aligns with the clinical reality that heart attacks and strokes are triggered by vulnerable lesions, not by diffuse atherosclerosis, and gives clinicians a data‑driven way to identify patients who may benefit from more aggressive therapy.

The tool is powered by CT‑Virtual Histology™ and is the only plaque‑analysis platform trained and validated against ground‑truth histology, the gold standard for tissue characterization. That scientific rigor earned Plaque‑IQ its FDA clearance for computed tomography angiography (CTA)‑based plaque morphology quantification, a distinction few competitors can claim. By delivering quantitative metrics such as lipid‑rich necrotic core volume and calcification density, the software translates imaging data into actionable biomarkers that can be integrated with existing risk models or used to guide interventions like stenting or intensive lipid‑lowering regimens.

From a business perspective, the commercial launch positions Elucid to capture a growing segment of the cardiovascular AI market, where hospitals are seeking tools that improve diagnostic precision while reducing invasive procedures. The lesion‑level insight may also accelerate adoption of Elucid’s upcoming FFR CT indication, creating a unified platform that links plaque morphology with functional ischemia assessment. As payers increasingly reward value‑based care, technologies that enable personalized, preventive strategies are likely to see stronger reimbursement pathways and broader clinical acceptance.